RSS Feeds
Esophageal Ulcers in AIDS
- Louis-Jean Couderc, MD;
- Evelyne Balloul, MD; and
- Isabelle Caubarrere, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Wilcox and colleagues [1] documented the high prevalence of idiopathic esophageal ulcers in patients with human immunodeficiency virus (HIV) infection and suggested that steroids be used in these patients. We previously reported that thalidomide was beneficial for esophageal ulceration and the HIV wasting syndrome [2, 3]. With treatment, the symptoms of aphthous ulceration, myalgia, and fever abated within 2 weeks. The patients required prolonged maintenance therapy because of recurrence when the daily thalidomide dose was tapered from 100 mg to 50 mg. No neurologic adverse effects occurred, although patients were treated simultaneously with azidothimidine. We suggest that thalidomide could be used as a first-line treatment for HIV-infected patients with idiopathic esophageal ulcers. Because of the well-known adverse effects of thalidomide, the use of the drug should be restricted to male patients who do not have peripheral neuropathy.
Louis-Jean Couderc, MD
Evelyne Balloul, MD
Isabelle Caubarrere, MD
Hopital Foch
92150 Suresnes, France
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright ©2004 by the American College of Physicians
